Synergene Therapeutics Inc Profile last edited on: 12/6/17
CAGE: 43DC1
UEI: W8E3G5851JK4
Business Identifier: Gene-based nanotech cancer therapeutics and diagnostics 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
9812 Falls Road Suite 114
Potomac, MD 20854
Potomac, MD 20854
| (202) 687-0356 |
| N/A |
| N/A |
Location: Single
Congr. District: 08
County: Montgomery
Congr. District: 08
County: Montgomery
Public Profile
SynerGene Therapeutics, Inc. is a biopharmaceutical company developing targeted diagnostics and therapeutics in the areas of cancer, vaccine delivery, and neurological disorders. SynerGeneâs proprietary nanocomplex actively targets receptors present on diseased cells, delivering therapeutic drugs specifically to targeted sites while avoiding healthy cells. The companyâs nanocomplex is able to deliver numerous molecular medicines, including plasmid DNA, siRNA/miRNA, AS ODN, small molecules, chemotherapy drugs, and imaging agents. SynerGene has two products in human clinical trials. As of 2014, SGT-53 is being tested in a Phase Ib trial at MCCRC in combination with chemotherapeutic agent docetaxel in patients with various solid tumors. A new Phase Ib/II trial testing SGT-53 in combination with gemcitabine in pancreatic cancer is expected to begin shortly. SGT-94 is testing the delivery of another tumor suppressor gene, RB94, in a Phase I trial in patients with genitourinary tumor
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
10-14Revenue Range
1M-1.5MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
1-4Awards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2014 | 1 | NIH | $222,900 | |
| Project Title: Crossing the BBB and Targeting CSCS for GBMTherapy | ||||
| 2011 | 1 | NIH | $498,331 | |
| Project Title: Sbir Proposal For Phs 2009-1 Topic 266 For A Targeted Nanocomplix For Early Dete | ||||
| 2010 | 1 | NIH | $498,331 | |
| Project Title: Sbir Proposal for Phs 2009-1 Topic 266 for a Targeted Nanocomplix for Early Dete | ||||
| 2009 | 1 | NIH | $199,978 | |
| Project Title: Sbir Proposal For Phs 2009-1 Topic 266 For A Targeted Nanocomplix For Early Dete | ||||
| 2009 | 1 | NIH | $199,735 | |
| Project Title: Targeted Nanocomplexed Iron Oxide For Early Detection With Hyperthermia Treatmen | ||||
Key People / Management
Raj Bawa
Esther H Chang -- Founder
Chris Leung
Chou-Chi Li
Maria Ruiz -- Executive Officer (Unknown)
Esther H Chang -- Founder
Chris Leung
Chou-Chi Li
Maria Ruiz -- Executive Officer (Unknown)
Company News
|
Feb
19
2013
|
Targeted Drug Delivery for Cancer Patients |
